Compare SFNC & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFNC | BEAM |
|---|---|---|
| Founded | 1903 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 1998 | 2019 |
| Metric | SFNC | BEAM |
|---|---|---|
| Price | $18.52 | $25.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 16 |
| Target Price | $22.83 | ★ $49.13 |
| AVG Volume (30 Days) | 984.4K | ★ 1.7M |
| Earning Date | 04-15-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.58% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $24,000.00 |
| Revenue This Year | $2,597.21 | N/A |
| Revenue Next Year | $4.06 | $35.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $17.00 | $13.53 |
| 52 Week High | $22.18 | $36.44 |
| Indicator | SFNC | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 31.49 | 39.74 |
| Support Level | $18.48 | $23.42 |
| Resistance Level | $18.66 | $25.69 |
| Average True Range (ATR) | 0.60 | 1.33 |
| MACD | -0.17 | -0.20 |
| Stochastic Oscillator | 5.77 | 0.23 |
Simmons First National Corp is a financial holding company. The company through its subsidiaries is engaged in providing banking services including consumer, real estate and commercial loans, checking, savings and time deposits. The company's loan portfolio comprises construction, single-family residential and commercial loans; non-real estate loans, nonaccrual and past due loans; and credit card loans, student loans and other consumer loans. It also offers various products and services such as trust services, investments, agricultural finance lending, equipment lending, insurance, consumer finance and small business administration lending. The business activity of the firm is functioned through the region of the United States.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.